|
Post by mnkdfann on Feb 26, 2019 8:23:53 GMT -5
Seeking Alpha summary report: seekingalpha.com/news/3437057-mannkind-misses-0_28-misses-revenueMannKind misses by $0.28, misses on revenue Feb. 26, 2019 8:09 AM ET|About: MannKind Corporation (MNKD)|By: Mamta Mayani, SA News Editor MannKind (NASDAQ:MNKD): Q4 GAAP EPS of -$0.06 misses by $0.28. Revenue of $16.03M (+253.9% Y/Y) misses by $7.48M.
|
|
|
Post by mnkdfann on Feb 26, 2019 8:15:57 GMT -5
See link for the rest, only posted an excerpt below: ca.finance.yahoo.com/news/mannkind-corporation-fourth-quarter-end-130000699.htmlMannKind Corporation Fourth Quarter and Year-End 2018 Earnings Call GlobeNewswire•February 26, 2019 Conference Call to Begin Today at 9:00 AM ET 4Q 2018 Total Revenues were $16.0 million; 254% growth vs. 4Q 2017 4Q 2018 Afrezza Net Revenue was $5.7 million; 28% growth vs. 4Q 2017 on a GAAP basis and 86% when adjusted for a one-time change in estimate recognized in 4Q 2017 4Q 2018 Collaborations and Services Revenue was $10.3 million 2018 Total Revenues were $27.9 million; 137% growth vs. 2017 2018 Afrezza Net Revenue was $17.3 million; 88% growth vs. 2017 2018 Collaborations and Services Revenue was $10.6 million Ended 2018 with $71.7 million in cash, cash equivalents and restricted cash Received $57.2 million in 2018 from license and research agreements with United Therapeutics and Cipla Achieved first-ever quarterly Afrezza gross profit in 4Q 2018 Reduced insulin purchase commitments for 2018 and 2019 by approximately $11.5 million WESTLAKE VILLAGE, Calif., Feb. 26, 2019 (GLOBE NEWSWIRE) -- MannKind Corporation (MNKD) today reported financial results for the fourth quarter and full year ended December 31, 2018. Fourth Quarter Results For the fourth quarter of 2018, total revenues were $16.0 million, reflecting Afrezza net revenue of $5.7 million and collaboration and services revenue of $10.3 million. Afrezza net revenue increased 28% on a GAAP basis compared to $4.5 million for the fourth quarter of 2017. In the fourth quarter of 2017, we recognized a $1.4 million change in estimate to Afrezza net revenue; when this adjustment is excluded, Afrezza net revenue increased 86% (non-GAAP) compared to the fourth quarter of 2017, primarily driven by higher product demand and a more favorable mix of cartridges. Collaborations and services revenue increased $10.2 million primarily attributable to the United Therapeutics licensing and research agreements. Afrezza cost of goods sold (COGS) was $5.0 million for the fourth quarter of both 2018 and 2017. Afrezza COGS in the fourth quarter of 2018 reflected a one-time charge of $2.0 million related to an amendment fee associated with our insulin supply agreement, offset by lower inventory write-offs in 2018 of $0.8 million and $0.7 million lower spending associated with manufacturing absorption. Afrezza gross profit was $0.7 million for the fourth quarter, the first quarterly gross profit recognized from Afrezza sales. When the one-time charge of $2.0 million related to the amendment fee is excluded, Afrezza gross profit was $2.7 million (non-GAAP) for the fourth quarter. ... The net loss for the fourth quarter of 2018 was $9.7 million, or $0.06 per share, compared to the $32.8 million net loss in the fourth quarter of 2017, or $0.28 per share. The lower net loss is mainly attributable to an increase in total revenues of $11.5 million and a decrease in total expenses of $9.6 million.
|
|
|
Post by mnkdfann on Feb 25, 2019 16:50:48 GMT -5
So, MNKD mentioned, but not in a positive way.
|
|
|
Post by mnkdfann on Feb 22, 2019 9:45:35 GMT -5
|
|
|
Post by mnkdfann on Feb 20, 2019 18:43:03 GMT -5
|
|
|
Post by mnkdfann on Feb 20, 2019 9:05:40 GMT -5
BTIG MedTech, Life Science & Diagnostic Tools 2019 Conference February 26-28, 2019 in Snowbird, UT. Participating from the Company will be its Chief Financial Officer, Steven B. Binder, and Chief Commercial Officer, Patrick McCauley in one-on-one meetings connecting management with institutional investors. Looks like fun. I guess Michael does not ski? www.btig.com/news/btig-medtech-life-science-diagnostic-tools-conference/I see the two events listed in the first post overlap and he can't be everywhere, so maybe he drew the short straw?
|
|
|
Post by mnkdfann on Feb 19, 2019 23:00:41 GMT -5
MNKD pays the rebates too so our overall costs go down as well. I bet we would be better off if there was an open and competitive playing field. As Peppy points out, many patients are better off with the direct pay option even if they have insurance coverage. Sure, but how long can Mannkind afford such deep discounts?
|
|
|
Post by mnkdfann on Feb 17, 2019 10:16:37 GMT -5
It is hard to believe that a year has already passed, but it is that time of year again. Nominations are open for the APPA Pharmaceutical Industry Awards: joinappa.com/awardsMike can't repeat as CEO of the year unless enough people nominate him in the first place. And only a few days left in which to do it! " The top 3 companies or individuals with the most nominations will make it to the polls for public voting. Nominations will close 12/31/18. Live voting will be open the second week of January 2019 and close March 1, 2019. Winners will be announced online March 4, 2019. Awards will be handed out during our 2019 Annual Convention. (Stay tuned)." Rereading my original post, I see the joinappa site originally said that the top 3 nominated would make it to voting. Either they changed that to top 5, or 2 of the 5 appearing in each category made it in to voting on another basis. Perhaps last year's winner and runner-up in each category were automatically entered?
|
|
|
Post by mnkdfann on Feb 16, 2019 13:46:46 GMT -5
Who nominated him? And how many votes does he have.. I can’t see from that link. Anyone could nominate, IIRC those with the most nominations made it to the competition itself. So I assume many people nominated him. I do not see vote counts being displayed. The page looks different from what I remember from last year. I think the changes might have been to keep vote counts secret this time around.
|
|
|
Post by mnkdfann on Feb 15, 2019 22:57:20 GMT -5
I'm honestly surprised given the sentiment towards Mike that was in December, but it looks like people stepped up and actually nominated Mike for CEO of the year once again. joinappa.com/awardsStart voting!
|
|
|
Post by mnkdfann on Feb 15, 2019 22:52:23 GMT -5
I think you need to look a little harder. Some progress was made in the T1 section A lot more is needed. T2s updates will be based of this years submissions to ADA2019.
Its a process. To get immediate results dedicated afrezza clinics are needed to bypass SOC. VDex is a small start. This needed to be done on a big scaled with proper funding.
Okay, but why hasn't Mannkind played ball and joined the Banting Circle (see link in OP) as has those other pharmas?
|
|
|
13g
Feb 14, 2019 19:21:25 GMT -5
olebob1 likes this
Post by mnkdfann on Feb 14, 2019 19:21:25 GMT -5
New: Cvi Holdings, Llc: 10,716,080 Company Overview Heights Capital Management, Inc. is a private equity and venture capital arm of Susquehanna International Group, LLP specializing in private investments in public equity in emerging growth companies. The firm typically invests in all the sectors with a particular focus on healthcare and technology companies. Heights Capital Management, Inc. was founded in 1996 and is based in San Francisco, California with an additional office in Bala Cynwyd, Pennsylvania According to Wikipedia and Susquehanna's own website, Susquehanna International Group is big on poker, e-sports, and bitcoin. The synergies with Mannkind speak for themselves.
|
|
|
Post by mnkdfann on Feb 13, 2019 8:45:41 GMT -5
Makes sense. They’re the ones least able to endure quickly escalating losses so more skittish. And they can’t manipulate the price using large scale naked shorting and bid/ask widen spread or hide their purchases in dark pools like the MMs. Spoiler Alert: There is a scene towards the end of Molly’s Game where the judge throws out the government’s case saying there was more crime committed on Wall Street in the morning than in all of Molly’s career. I enjoyed that. It would have been even better if he had gone into detail why he said it. This isn't how you do spoiler alerts. You're supposed to mention the name of the movie BEFORE you say "spoiler alert". It is difficult to stop reading in the middle of a sentence. Thank you for telling me about an interesting movie I never heard about. And thanks for spoiling it 2 seconds later I feel for you, still, I'm not sure spoiler alerts apply to biographical movies, or those widely written about in the media and reported about in the news. Most people who went to the movie were probably already aware of the story and how it ended.
|
|
|
Post by mnkdfann on Feb 12, 2019 8:40:35 GMT -5
I suggested something along those lines a few weeks back: mnkd.proboards.com/post/169248Some others probably also mentioned the same sort of idea from time to time in the past. It's hard to believe Mannkind never thought of this. So perhaps it either simply has not worked, or they decided it wasn't the way to go. That was initiated when the ACA started. Drs. realized they will not be making $2 Million a year and only $1 Million so they started a VIP Service. You pay an annual or monthly retainer and have 24 hour access to your doctor. Concierge medicine existed long before the ACA. www.seattlemag.com/article/why-concierge-care-becoming-more-popular-seattleConcierge medicine has its roots in Seattle, beginning in the mid-1990s when former Seattle SuperSonics physician Dr. Howard Maron and Dr. Scott Hall founded concierge clinic MD2. A few years later, Virginia Mason Medical Center began developing its program, one of the country’s first concierge practices housed within a multidisciplinary academic hospital. Since then, it’s estimated that some 12,000 doctors nationwide have adopted a concierge model.
|
|
|
Post by mnkdfann on Feb 11, 2019 23:26:12 GMT -5
Here's an idea that I have not seen discussed much on this board: concierge medicine. Generally, clients of concierge physicians are wealthy and are more than apt to afford premium medications either with or without insurance. How strategic would it be to have a handful of sales reps connect with concierge physicians? Although they may make up only a minority of the potential market, I imagine this would be a "high yield" patient population (i.e., no financial barriers). Perhaps MNKD is or already has explored this route. I suggested something along those lines a few weeks back: mnkd.proboards.com/post/169248Some others probably also mentioned the same sort of idea from time to time in the past. It's hard to believe Mannkind never thought of this. So perhaps it either simply has not worked, or they decided it wasn't the way to go.
|
|